 |
|
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin in Close Proximity to Surgery vs Warfarin in Hip Arthroplasty Patients
A Double-blind, Randomized Comparison
Russell D. Hull, MBBS, MSc;
Graham F. Pineo, MD;
Charles Francis, MD;
David Bergqvist, MD, PhD;
Carin Fellenius, RN, MEd;
Karin Soderberg, RN;
Anna Holmqvist, BSc;
Michael Mant, MB, ChB;
Richard Dear, MBBS;
Barry Baylis, MD;
Andrew Mah, BSc;
Rollin Brant, PhD;
for the North American Fragmin Trial Investigators
Arch Intern Med. 2000;160:2199-2207.
ABSTRACT
| |
Background Based on the current understanding that venous thrombosis starts perioperatively, administration of just-in-time low-molecular-weight heparin immediately before or in close proximity after hip arthroplasty may be more effective than usual clinical practice.
Methods We performed a randomized, double-blind trial comparing subcutaneous dalteparin sodium given once daily immediately before or early after surgery with the use of postoperative warfarin sodium in 1472 patients undergoing elective hip arthroplasties. The primary end point was deep vein thrombosis detected using contrast venography performed after surgery (mean, 5.7 days) in each group.
Results The frequencies of deep vein thrombosis for patients with interpretable venograms receiving preoperative and postoperative dalteparin for all deep vein thrombosis were 36 (10.7%) of 337 (P<.001) and 44 (13.1%) of 336 (P<.001), respectively, vs 81 (24.0%) of 338 for warfarin; for proximal deep vein thrombosis, 3 (0.8%) of 354 (P = .04) and 3 (0.8%) of 358 (P = .03), respectively, vs 11 (3.0%) of 363. Relative risk reductions for the dalteparin groups ranged from 45% to 72%. Symptomatic thrombi were less frequent in the preoperative dalteparin group (5/337 patients [1.5%]) vs the warfarin group (15/338 patients [4.4%]) (P = .02). Serious bleeding was similar among groups. Increased major bleeding at the surgical site was observed for patients receiving preoperative dalteparin vs warfarin (P = .01).
Conclusions A modified dalteparin regimen in close proximity to surgery resulted in substantive risk reductions for all and proximal deep vein thrombosis, compared with warfarin therapy. Such findings have not been observed with low-molecular-weight heparin therapy commenced 12 hours preoperatively or 12 to 24 hours postoperatively vs oral anticoagulants. Increased major but not serious bleeding occurred in patients receiving preoperative dalteparin. Dalteparin therapy initiated postoperatively provided superior efficacy vs warfarin without significantly increased overt bleeding.
INTRODUCTION
EPIDEMIOLOGICAL data demonstrate that perioperative and postoperative venous thrombosis are common in high-risk patients undergoing surgery.1-5 In the absence of thromboprophylaxis, this disorder occurs in 40% to 60% of patients receiving hip implants.5-6 Prophylactic recommendations against venous thromboembolism in patients undergoing hip arthroplasty include warfarin sodium and subcutaneous low-molecular-weight heparin therapy.5-6
Clinical practice differs in North America and Europe regarding the initiation time of prophylaxis in patients undergoing surgery. Use of low-molecular-weight heparin has been evaluated in patients undergoing hip arthroplasty in multiple level 1 randomized trials.7-29 European practice has largely consisted of commencement of low-molecular-weight heparin therapy 12 hours preoperatively.8-11,13-16,18, 21-24,26-29 The European approach recognizes that deep vein thrombosis typically commences perioperatively and that preoperative prophylaxis optimizes antithrombotic effectiveness.30-31 Delayed initiation (12-24 hours postoperatively) of low-molecular-weight heparin prophylaxis is standard practice in North America to minimize bleeding risk.7, 12, 17, 19-20,32 This disparity in clinical practice has led to the expressed need (by the International Consensus Statement) for a level 1 randomized trial evaluating the time of initiation of low-molecular-weight heparin thromboprophylaxis.6 A recent unblinded, randomized trial suggests that low-molecular-weight heparin prophylaxis is superior to warfarin; in this context, both regimens were commenced preoperatively.25
It is possible that low-molecular-weight heparin administered in closer proximity to surgery, in the immediate preoperative or early postoperative period, may be more effective than current clinical practice. This just-in-time concept harmonizes with the current understanding that the risk for thrombosis starts perioperatively.
To date no studies have compared immediate preoperative or early postoperative commencement of low-molecular-weight heparin vs warfarin prophylaxis.33 We performed a double-blind randomized trial evaluating the following 3 differing pharmacological approaches: once-daily subcutaneous dalteparin sodium therapy initiated in the immediate preoperative or early postoperative period, or warfarin administered during the acute hospital stay.
PATIENTS AND METHODS
STUDY DESIGN
This study was a multicenter, randomized, double-blind clinical trial comparing 3 prophylactic regimens in patients undergoing hip arthroplasty. Regimens consisted of dalteparin sodium (Fragmin; Pharmacia & Upjohn, Stockholm, Sweden) and warfarin sodium (Coumadin; Dupont Pharmaceuticals, Wilmington, Del). Twenty-nine centers in the United States and Canada participated in the trial. The efficacy and safety of these approaches were evaluated during the acute hospital stay (day 0-6 ± 2). A second concurrent study investigated extended out-of-hospital prophylaxis; this is beyond the scope of this article and will be reported separately.
The protocol was approved by each center's institutional review board.
PATIENTS
We enrolled consecutive eligible patients aged at least 18 years and scheduled for elective unilateral total hip arthroplasty (primary or revision) who gave informed consent. Patients were eligible if they had none of the following: documented bleeding within 3 months before surgery; known hypersensitivity to heparin, low-molecular-weight heparin, warfarin, or contrast media; defective hemostasis (eg, thrombocytopenia [<100 x 109/L]); ongoing anticoagulants; pregnancy or breastfeeding; clinically significant hepatic dysfunction; renal insufficiency (serum creatinine level, >150 µmol/L [>1.7 mg/dL]); severe hypertension (diastolic blood pressure, >120 mm Hg); septic endocarditis; weight of less than 40 kg; eye, ear, or central nervous system surgery within 1 month before surgery; diseases with unfavorable prognosis (eg, malignant neoplasms or other intercurrent disease making study participation impractical or medically complicated); inability to follow instructions or perform procedures, including self-injections required during the home prophylaxis study; simultaneous participation in another pharmacological study or use of any investigational drug within 30 days before surgery; previous randomization into this study; or use of pneumatic compression stockings.
Of the 5114 patients undergoing screening, 1585 consented to participate. The remaining did not participate because of ongoing anticoagulant use or defective hemostasis (258 patients); diseases with unfavorable prognosis or intercurrent diseases making participation impractical (264 patients); inability to perform procedures (eg, self-injections) required by the study (337 patients); participation declined (1990 patients); previous randomization into the trial (98 patients); or miscellaneous reasons (582 patients).
On the day of surgery, another 84 patients were ineligible due to postponement of surgery (24 patients), miscellaneous reasons (20 patients), and withdrawal of informed consent (40 patients).
Before randomization, the 1501 eligible patients were stratified according to study center. We used a randomized, computer-derived treatment schedule to assign treatment regimens. To obtain continuing balance of treatments, the randomization list was divided into consecutive blocks.
TREATMENT REGIMENS
Patients randomized to preoperative dalteparin sodium received their initial 2500-IU subcutaneous injection within 2 hours before surgery (mean ± SD, 49 ± 49 minutes) and only if the spinal procedure was uncomplicated.34 These patients received a second dose of dalteparin sodium, 2500 IU, subcutaneously at least 4 hours postoperatively (mean ± SD, 6.6 ± 2.3 hours). Patients randomized to postoperative dalteparin received a placebo injection immediately before surgery as described above. Their first active dalteparin injection was administered at least 4 hours postoperatively (mean ± SD, 6.6 ± 2.4 hours). On subsequent days, all patients receiving dalteparin sodium were given 5000 IU subcutaneously once daily each morning.
Patients randomized to warfarin received an initial dose postoperatively on the evening of surgery day. The initial dose was 10 mg, except for patients aged 70 years or older or weighing less than 57 kg, who received a 5-mg dose. Thereafter, warfarin doses were adjusted daily using a prescriptive protocol according to the prothrombin international normalized ratio (INR) findings with a predefined warfarin nomogram.35 Warfarin doses were adjusted daily to maintain an INR from 2.0 to 3.0.
Patients randomized to receive warfarin also received subcutaneous placebo injections. Patients randomized to receive dalteparin also received placebo capsules (warfarin and its placebo were encapsulated to maintain blinding). To maintain blinding of each patient's treatment assignment, the prothrombin time results were not recorded in the patient's chart or reported to the health care team.17 The INR results were reported only to an unblinded anticoagulant monitor not involved in assessing outcomes. Daily warfarin dose adjustments or dummy orders (for patients receiving placebo capsules for warfarin) were made by the unblinded anticoagulant monitor according to a prescribed dosage schedule. Thus, the use of placebo capsules and injections and the assignment of an independent anticoagulant monitor to adjust INR values maintained double-blinding throughout the study.
Use of anticoagulants (other than study treatment), aspirin, dipyridamole, ticlopidine hydrochloride, and pneumatic compression devices was prohibited during the study. The use of nonsteroidal anti-inflammatory drugs was strongly discouraged.
SURVEILLANCE AND FOLLOW-UP
All patients were examined daily. Bleeding episodes, perioperative and postoperative blood loss, blood replacement requirements, and platelet levels were documented. Patients in whom overt symptoms and/or signs of deep vein thrombosis or pulmonary embolism developed underwent objective testing. Noninvasive surveillance for deep vein thrombosis was not performed in patients without clinically suspected deep vein thrombosis, because results of such screening are relatively insensitive in this context.36-41
Bilateral ascending radiocontrast venography was mandated by the protocol and was performed on day 6 ± 2 or at the time of discharge from hospital if this occurred earlier. Venography was performed and the results were interpreted as described elsewhere.42-43 Constant intraluminal filling defects in the popliteal, superficial femoral, common femoral, external iliac, or common iliac veins (with or without constant intraluminal filling defects in the deep veins of the calf) were classified as proximal vein thrombosis; those confined to the deep veins of the calf were classified as calf vein thrombosis. Venographic findings were classified as normal if the deep veins of the calf and the proximal deep veins (including the popliteal, superficial femoral, common femoral, external iliac, and common iliac veins) were visualized adequately in both legs.
Venograms were interpreted by the local radiologist and an independent, blinded central reader (R.D.H.). Disagreements between the local radiologist and the central reader were resolved by a second blinded independent central interpretation; this second reading was decisive. The same process occurred in occasional patients with suspected pulmonary embolism who underwent lung scanning or pulmonary angiography.
Bleeding was documented according to a widely used international classification.44-45 Bleeding was classified as major if it was clinically overt and associated with a decrease in hemoglobin level of 20 g/L or more or required transfusion of 2 U of blood or more; if it was intracranial, intraocular, intraspinal or retroperitoneal; or if it occurred into a prosthetic joint. Bleeding was defined as minor if it was clinically overt without meeting the major bleeding criteria and as trivial if it was clearly of no consequence. Wound hematomas that occurred in the absence of clinically overt blood loss were documented, as were associated complications (infection, persistent drainage, wound dehiscence, and prolongation of the hospital stay). Two central committee members not involved in the patient's care independently adjudicated the bleeding data using the international classification44-45; disagreements were resolved by the independent safety monitor (D.B.).
The frequency of major bleeding was also reported by the site investigator. This differed from the centrally adjudicated bleeding rates as the site investigator decided whether the bleeding was clinically important based on clinical judgment. In contrast, the centrally adjudicated bleeding rates were determined only by the information reported in the case report forms using the criteria described above, which were applied to all reports of bleeding independent of the site investigators' clinical judgment.
In a previous study25 where low-molecular-weight heparin was given within 2 hours before surgery and where safety events were reported based on clinical judgment, there was an increased number of transfusions given in the low-molecular-weight heparin group compared with the warfarin group. The reason, however, for the increased transfusions could not be identified by the recorded blood loss or incidence of major bleeding. For this reason, central adjudication of safety events in our trial included all events from the commencement of surgery up to postoperative day 8.
Serious bleeding as defined by Eriksson et al26 is also provided in the results. Serious bleeding is defined to include patients receiving transfusion of more than 5 U of whole blood or concentrates of red blood cells perioperatively, patients receiving transfusion of more than 7 U of whole blood or concentrates of red blood cells anytime after surgery, or patients with total blood loss of more than 3500 mL.26
If patients had clinically suspected venous thrombosis, objective testing with duplex ultrasonography or ascending contrast venography was required. For patients with suspected pulmonary embolism, objective documentation was required using high-probability lung scan, pulmonary angiogram, or autopsy findings. The methods of performing and interpreting the objective tests are reported in detail elsewhere.44, 46-48
STATISTICAL ANALYSIS
We estimated that 1500 patients (500 per treatment group) would be required. This was based on deep vein thrombosis rates on day 6 ± 2 of 12% vs 20% for patients receiving preoperative dalteparin vs warfarin, respectively. The sample size required for a detectable treatment difference with a power of 80% at the 5% significance level (2-tailed test) requires at least 354 patients per group. If an inevaluable frequency of 20% is considered, about 442 patients are required for each group.
The uncorrected  2 was used to compare frequencies of venous thrombosis, bleeding, and death among treatment groups.49 The Fisher exact test was not used, as expected event frequencies exceeded 5 in all cases. Analysis of deviance based on logistic regression was used to evaluate center variability.49 All P values were 2-tailed. Ninety-five percent confidence intervals for the difference between 2 treatment groups in the incidence of venous thrombosis and bleeding complications were calculated with the normal approximation to the binomial distribution.49
RESULTS
Of 1501 consecutive randomized patients, 496, 487, and 489 patients receiving preoperative and postoperative dalteparin and warfarin, respectively, characteristics of the treatment groups were similar on entry (Table 1). Twenty-nine patients were randomized but did not receive study medication; this occurred because of traumatic spinal tap (1, 3, and 3 patients per group, respectively), cancelled operation, (0, 2, and 1 patients, respectively), presence of exclusion criteria (1, 1, and 1 patient, respectively), withdrawn consent (2, 1, and 3 patients, respectively), or miscellaneous reasons making the patient ineligible (4, 2, and 4 patients, respectively).
|
|
|
|
Table 1. Clinical Characteristics of Study Patients*
|
|
|
The proportion of patients undergoing venography and the adequacy of venography are shown in Table 2.
|
|
|
|
Table 2. Deep Vein Thrombosis by Venography, Objectively Documented Symptomatic Venous Thromboembolism, and Death*
|
|
|
DEEP VEIN THROMBOSIS BY VENOGRAPHY
For patients with interpretable venograms, the frequencies of deep vein thrombosis in patients receiving preoperative and postoperative dalteparin and warfarin for all deep vein thrombosis were 36 (10.7%) of 337, 44 (13.1%) of 336, and 81 (24.0%) of 338, respectively (P<.001 for both preoperative and postoperative dalteparin vs warfarin); for proximal deep vein thrombosis, 3 (0.8%) of 354, 3 (0.8%) of 358, and 11 (3.0%) of 363 (P = .04 and P = .03 for preoperative and postoperative dalteparin vs warfarin, respectively). The relative risk reductions for the dalteparin groups compared with the warfarin group ranged from 45% to 72% (Table 2).
Since thrombosis rates in both dalteparin arms were consistent, we pooled results for both arms (Table 2).
Among centers with 30 or more patients (9 centers), rates of deep vein thrombosis in the 3 treatment arms ranged from 0% to 7.1% for proximal deep vein thrombosis, and 4.4% to 44.8% for deep vein thrombosis overall. Analysis of all centers using logistic regression showed no evidence of interaction between treatment and center.
BLEEDING COMPLICATIONS
Bleeding complications are shown in Table 3 and Table 4. Increased major bleeding was observed for the preoperative dalteparin group compared with the warfarin group (Table 3) (P = .01).
|
|
|
|
Table 3. Frequency of Bleeding*
|
|
|
|
|
|
|
Table 4. Description of Centrally Adjudicated Bleeding*
|
|
|
Major bleeding events documented by the local site investigators were infrequent and similar among groups. Serious bleeding episodes were also infrequent and similar among groups (Table 3).
Minor and trivial bleeding occurred infrequently (Table 3). Wound hematoma rates were similar among groups, and complicated wound hematomas were rare (Table 3).
Mean hemoglobin levels and blood loss were similar among groups (Table 5). The proportion of patients receiving transfusions was significantly higher (Table 5) for the dalteparin groups compared with the warfarin group (P = .001 and P = .002, respectively). Transfusion volumes were similar among groups (Table 5).
|
|
|
|
Table 5. Blood Loss, Blood Replacement, Transfusion Frequency, Hemoglobin Levels, and Incidence of Thrombocytopenia*
|
|
|
The frequency and distribution of thrombocytopenia (platelet count, <100 x 109/L) is shown in Table 5. Most had concomitant blood loss and decreased hemoglobin levels.
No patient had spinal or epidural hematomas or bleeding associated with neurologic defects.
CLINICALLY EVIDENT THROMBOEMBOLIC EVENTS
Objectively documented deep vein thrombosis was observed in 161 patients; only 30 (18.6%) of these patients were symptomatic (Table 2). Thrombosis in 27 of these 30 patients was documented using venography; in 3, using duplex ultrasound. Symptomatic thrombi occurred significantly less frequently in the preoperative dalteparin vs warfarin groups (P = .02) (Table 2).
No patient had objectively documented pulmonary embolism.
PROTHROMBIN TIME (INR)
Warfarin therapy was adjusted to achieve an INR of 2.0 to 3.0; INR results exceeded 2.0 in 86.0% of patients by day 6.
COMMENT
Our findings demonstrate that dalteparin in the immediate preoperative or early postoperative period was more effective than warfarin for preventing deep vein thrombosis in patients undergoing hip arthroplasty. Frequencies of all and proximal deep vein thrombosis were reduced substantially in patients receiving dalteparin; the relative risk reductions for all and proximal deep vein thrombosis associated with preoperative dalteparin vs warfarin were 55% (P<.001) vs 72% (P = .04), respectively; with postoperative dalteparin vs warfarin, 45% (P<.001) vs 72% (P = .03), respectively. The relative risk reduction for the combined dalteparin group vs warfarin was 50% (P<.001) for deep vein thrombosis and 72% (P = .009) for proximal vein thrombosis. Symptomatic thrombi occurred less frequently in the preoperative dalteparin group (5/337 patients [1.5%]) vs the warfarin group (15/338 patients [4.4%]) (P = .02).
Venography was performed early in our trial (mean, 5.7 days), but the rates of all and proximal deep vein thrombosis observed in the warfarin group were similar to those observed by means of venography performed in patients undergoing hip arthroplasty on days 7 through 14.17, 21, 25, 50
The all and proximal deep vein thrombosis rates for the dalteparin groups were reduced markedly compared with the warfarin group and likely reflect the initiation of dalteparin therapy in close proximity to surgery. Warfarin and low-molecular-weight heparin thromboprophylaxis are recommended by the 1998 American College of Chest Physicians Consensus Conference for patients undergoing elective hip surgery.5 Warfarin traditionally has been used; however low-molecular-weight heparin regimens are assuming increasing predominance. At the time of our clinical trial program implementation, warfarin was the dominant prophylactic approach used in North America. The use of a delayed prophylaxis regimen of low-molecular-weight heparin was not standard clinical practice.
In North America, low-molecular-weight heparin prophylaxis in patients undergoing hip arthroplasty is usually delayed postoperatively for at least 12 to 24 hours to minimize bleeding.7, 12, 17, 19-20 Despite high-risk doses or a twice-daily regimen, these regimens have not shown significant reductions in all or proximal deep vein thrombosis rates compared with warfarin or unfractionated heparin prophylaxis in patients undergoing hip arthroplasty.7, 12, 17, 19-20
We administered low-molecular-weight heparin postoperatively in close proximity to surgery (mean ± SD, 6.6 ± 2.4 hours). To minimize bleeding, the initial postoperative dalteparin sodium dose was only half the high-risk dose (2500 IU); the usual high-risk dose (5000 IU subcutaneously) was resumed the next day. We found that postoperative dalteparin administered early in close proximity to surgery was more effective than warfarin, without a significant increase in major bleeding. This finding is in contrast to studies using 12- to 24-hour postoperative low-molecular-weight heparin regimens that have failed to demonstrate significant risk reductions against oral anticoagulants,17, 21 while providing supportive evidence of the superiority of the close proximity strategy.
Dalteparin administered in close proximity to surgery also resulted in unusually low proximal deep vein thrombosis rates compared with those found in European randomized trials that initiated low-molecular-weight heparin therapy 12 hours preoperatively in patients undergoing hip arthroplasty.8-11,13-16,18, 21-24,26-29 Low-molecular-weight heparin therapy commenced the evening before hip implant surgery was compared with acenocoumarol therapy commenced the day before surgery in an open-label randomized trial in Europe21; results of venographic evaluation showed similar proximal and all deep vein thrombosis rates (6.5% vs 5.8%, respectively, and 16.5% vs 19.5%, respectively). Dalteparin therapy commenced 2 hours preoperatively in an open-label hip implant study was significantly more effective than warfarin therapy commenced the evening before surgery.25 These findings suggest that our thromboprophylaxis approach in close proximity to surgery is more effective.
Recently, hirudin administered immediately before hip arthroplasty surgery was compared with low-molecular-weight heparin therapy commenced 12 hours preoperatively.26 The just-in-time thrombin-inhibitor regimen was more effective, and serious bleeding episodes were infrequent; these observations are also consistent with our findings.
Major bleeding at the operative site was significantly more frequent in patients receiving preoperative dalteparin vs warfarin using central adjudication (Table 3 and Table 4). The centrally adjudicated major bleeding rate in the warfarin group on days 0 through 1 was 4.1%. Since the first warfarin dose was not administered until the night after surgery, this bleeding rate largely reflected usual bleeding associated with surgery. The central adjudicators lacked the clinical perspective at the bedside and may have overestimated major bleeding from the case report forms because of the difficulty of discriminating between usual operative bleeding and increased bleeding for the perioperative and immediate postoperative interval. Major bleeding reported by site investigators based on clinical judgment using the same criteria as the central adjudicators was low and similar among groups. Serious bleeding episodes as defined by Eriksson et al26 were infrequent and similar among groups. No deaths occurred among patients with major blood loss.
The frequency of major bleeding postoperatively is similar to that reported in the cited literature for patients receiving postoperative low-molecular-weight heparin or warfarin prophylaxis after hip-arthroplasty surgery in North America.12, 17, 19 The frequency of minor and trivial bleeding was low and similar among groups. Uncomplicated wound hematoma rates were similar among the groups. Complicated wound hematomas occurred infrequently. Blood transfusions were significantly more frequent in the dalteparin groups (Table 5).
Our findings cannot be attributed to bias; randomization was successful because the baseline characteristics of the patients were comparable among groups and the study was conducted in double-blind fashion to avoid bias in searching for or interpreting outcome events. Our findings cannot be attributed to inadequate administration of warfarin, as most patients (86.0%) underwent adequate anticoagulation by day 6. The proportion of patients undergoing evaluation, of those eligible, is comparable to that of other rigorous randomized trials evaluating pharmacological interventions. The frequencies of symptomatic venous thromboembolism were inevitably low as a result of case finding by means of venography, leading to early treatment of deep vein thrombosis.
The proportion of patients with adequate venograms was high (86.6% for proximal visualization of those who underwent venography) and can be attributed to education and feedback provided to participating radiologists throughout the course of the study. Another high-quality double-blind trial reported venogram adequacy rates similar to ours.26
Recently in the United States, concern has arisen about the associated use of neuraxial anesthesia and low-molecular-weight heparin prophylaxis because of a reported cluster of spinal hematomas.51-53 A twice-daily low-molecular-weight heparin regimen has prevailed in the United States, whereas a once-daily regimen has prevailed in Europe; the latter has not been associated with a reported cluster of spinal hematomas. This intercontinental difference may reflect the dominant regimens used.
Our findings indicate that a once-daily low-molecular-weight heparin regimen is sufficient. The once-a-day postoperative regimen has the advantages that accumulation is less likely, that it is effective, and that the postoperative bleeding rates are low. Since half of the usual high-risk dose of dalteparin is given the day of surgery, and the average time of initiation of therapy after spinal anesthesia was 9 hours, the modified postoperative regimen of once-daily dalteparin reported herein may be a safe approach in avoiding spinal hematoma. The cost-effectiveness of in-hospital prophylaxis is beyond the scope of this article and should be addressed separately.
CONCLUSIONS
Low-molecular-weight heparin prophylaxis administered preoperatively or postoperatively using a modified dalteparin regimen in close proximity to hip arthroplasty resulted in substantive risk reductions for all and proximal deep vein thrombosis compared with warfarin. Such findings have not been observed with low-molecular-weight heparin therapy commenced 12 hours preoperatively or 12 to 24 hours postoperatively. Major44-45 but not serious26 bleeding occurred more frequently in patients receiving dalteparin in the immediate preoperative period. Dalteparin therapy initiated postoperatively provided superior efficacy vs warfarin, without significantly increased overt bleeding.
AUTHOR INFORMATION
Accepted for publication November 4, 1999.
Support for this trial was provided through a grant-in-aid by Pharmacia & Upjohn to the University of Calgary.
The following is a list of the additional coauthors: David Rosenbloom, PharmD, Orthopedic & Arthritic Hospital, Toronto, Ontario; Peter Hanson, MD, Groosmont Hospital and Saddleback Medical Research, San Diego, Calif; Frank Smith, MB ChB, Hamilton Health Sciences Corporation and McMaster University, Hamilton, Ontario; Linda Vickars, MD, St Paul's Hospital, Vancouver, British Columbia; David Green, MD, PhD, Northwestern University, Chicago, Ill; Frank Ariosta, MD, Staten Island University Hospital, Staten Island, NY; William Fisher, MD, Royal Victorian Hospital, Montreal, Quebec; David Ayers, MD, State University of New York Health Science Center at Syracuse; Terence Sparling, MD, Burnaby Hospital Regional Cancer Center, Burnaby, British Columbia; Louis Desjardins, MD, Centre Hospitalier de l'Université Laval, Ste Foy, Quebec; Robert Lavender, MD, University of Arkansas for Medical Sciences, Little Rock; John McCutchen, MD, South Eastern Clinical Research Consultants, Maitland, Florida; Bernard Stulberg, MD, Cleveland Center for Joint Reconstruction, Cleveland, Ohio; William Allen, MD, Pharmacotherapy Research Associates, Zanesville, Ohio; Scott Berkowitz, MD, Duke University Medical Center, Durham, NC; Robert Lerner, MD, New York Medical College, Valhalla; Clifford Colwell, MD, Scripps Clinic, La Jolla, Calif; and Melvin Tonkon, MD, Anaheim Heart & Research Institute, Anaheim, Calif.
A list of additional participants of the North American Fragmin Trial appear below. Special thanks go to Gary Raskob, PhD, of the Clinical Epidemiology Unit, University of Oklahoma Health Sciences Center, Oklahoma City.
| Additional Participants in the North American Fragmin Trial
University of Alberta Hospital, Edmonton: L. Boshkov, P. Donahue, V. Jordan, M. MacDonald, D. Russell; Peter Lougheed Center and Calgary General Hospital, Calgary, Alberta: J. Dear, D. McKeage, J. Walsh; Foothills Medical Center, Calgary: J. Gardner, J. Lemaire, M. McDonald; Orthopedic & Arthritic Hospital, Toronto, Ontario: M. Ford, C. Bakuska, J. Clark; University of Rochester Medical Center, Rochester, NY: A. Boyd, J. Brennan, E. DeMara, K. Kaplan, V. Marder, A. Rapoport; Grossmont Hospital and Saddleback Medical Research, San Diego, Calif: J. Graydon, B. Hazer, P. Kuey, T. Sheen; Hamilton Health Sciences Corporation and McMaster University, Hamilton, Ontario: N. Marchetti, L. A. Reynolds, D. Rosenbloom; St Paul's Hospital, Vancouver, British Columbia: P. Galbraith, D. Michaels; Northwestern University, Chicago, Ill: M. Arron, R. Tulabya; Staten Island University Hospital, Staten Island, NY: A. Cernaianu, F. Huie; Royal Victoria Hospital, Montreal, Quebec: R. Brassard, A. Brox, C. Shustik, J. Sinclair, G. Sprull; State University of New York Health Science Center at Syracuse: D. Murray, M.Van Glynn; Southern Illinois University School of Medicine, Springfield: G. Allan, C. Bears, G. Caronis, J. Galles, K. Olin, B. Werries; Burnaby Hospital Regional Cancer Center, Burnaby, British Columbia: W. Leong, E. Scofield; Centre Hospitalier de l'Université Laval, Ste Foy, Quebec: N. Fortier, L. St Pierre; Johns Hopkins University, Baltimore, Md: M. Mont, D. Lennox, D. Hungerford, L. Jones; University of Arkansas for Medical Sciences, Little Rock: C. Harness, T. Holcomb, C. Nelson; South Eastern Clinical Research Consultants, Maitland, Florida: J. Byrnes, J. Simmons; St Joseph's Hospital, Brantford, Ontario: C. Whately, J. Collingwood, L. Dimmel; Northwest Physicians Research Unit, Missoula, Mont: D. McGee, H. Elzinga, M. Kreeger; The Damluji Research Center, San Diego: M. Skyhar, G. Dennish, K. Harden; Cleveland Center for Joint Reconstruction, Cleveland, Ohio: G. Swope, A. Tahir; Pharmacotherapy Research Association, Zanesville, Ohio: K. Crist, M. Crist, C. Cunningham; Health Sciences Center, St Johns, Newfoundland: L. Whitman, S. Murphy, J. Watson; Duke University Medical Center, Durham, NC: T. L. Ortel, D. D. Smith, T. P. Vail, A. C. Womack; New York Medical College, Valhalla: J. Nelson, E. Scorcia; Scripps Clinic, La Jolla, Calif: M. Hardwick, B. Morris, R. Sarnoff; Anaheim Heart & Research Institute, Anaheim, Calif: T. Katzman, V. McKinnon, D. Simons; LDS Hospital, Salt Lake City, Utah: G. Elliott, N. Kitterman, S. Yeates; Uppsala University, Uppsala, Sweden: D. Bergqvist (safety monitor); Pharmacia & Upjohn, Stockholm, Sweden, Kalamazoo, Mich, Toronto, Ontario: C. Björk, P. Carrothers, L. Pan, J. Svensson, C. Taylor; Thrombosis Research Unit, University of Calgary, Calgary: S. Boyle, M. Butcher, C. Lerede, M. McDonald, A. Powell, J. Sheldon, V. Stagg, J. White, C. Wrona.
|
|
Reprints: Russell D. Hull, MBBS, MSc, Thrombosis Research Unit, 601 S Tower, Foothills Hospital, 1403-29 St NW, Calgary, Alberta, Canada T2N 2T9 (e-mail: http://www.ucalgary.ca/UofC/faculties/medicine/TRU).
From the Thrombosis Research Unit, University of Calgary (Drs Hull, Pineo, and Brant and Mr Mah), Peter Lougheed Center and Calgary General Hospital (Dr Dear), and Foothills Medical Center (Dr Baylis), Calgary, Alberta; University of Rochester Medical Center, Rochester, NY (Dr Francis); Uppsala University, Uppsala, Sweden (Dr Bergqvist); Pharmacia & Upjohn, Stockholm, Sweden (Mss Fellenius, Soderberg, and Holmqvist); and University of Alberta Hospital, Edmonton, Alberta (Dr Mant).
REFERENCES
| |
1. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med. 1991;151:933-938.
FREE FULL TEXT
2. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med. 1992;152:1660-1664.
FREE FULL TEXT
3. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992;232:155-160.
ISI
| PUBMED
4. Gallus AS, Salzman EW, Hirsh J. Prevention of venous thromboembolism. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadephia, Pa: JB Lippincott; 1994:1331-1335.
5. Clagett GP, Anderson FA, Geerts W, et al. Prevention of venous thromboembolism. Chest. 1998;114(5 suppl):531S-560S.
6. Prevention of venous thromboembolism: international consensus statement. Int Angiol. 1997;16:3-38.
ISI
| PUBMED
7. Turpie AGG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986;315:925-929.
ABSTRACT
8. Planes A, Vochelle N, Mazar F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement thrombosis and haemostasis. Thromb Haemost. 1988;60:407-410.
ISI
| PUBMED
9. Danish Enoxaparin Study Group. Low-molecular-weight heparin (enoxaparin) vs dextran 70: the prevention of postoperative deep vein thrombosis after total hip replacement. Arch Intern Med. 1991;151:1621-1624.
FREE FULL TEXT
10. Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties. Acta Orthop Scand. 1991;62:33-38.
ISI
| PUBMED
11. Eriksson BI, Kälebo P, Anthmyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg Am. 1991;73:484-493.
FREE FULL TEXT
12. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991;114:545-551.
13. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ. 1991;303:543-548.
14. Planes A, Vochelle N, Fagola M, Feret J, Bellaud M. Prevention of deep vein thrombosis after total hip replacement: the effect of low-molecular-weight heparin with spinal and general anaesthesia. J Bone Joint Surg Br. 1991;73:418-423.
15. Torholm C, Broeng L, Jorgensen PS, et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery: a placebo controlled study. J Bone Joint Surg Br. 1991;73:434-438.
16. German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. Arch Orthop Trauma Surg. 1992;111:110-120.
17. Hull RD, Raskob GE, Pineo GF, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993;329:1370-1376.
FREE FULL TEXT
18. Planes A. Comparison of antithrombotic efficacy and haemorrhagic side effects of Clivarin vs enoxaparin in patients undergoing total hip replacement surgery. Blood Coagul Fibrinolysis. 1993;4(suppl):S33-S38.
19. Spiro TE, Johnson CJ, Christie MJ, et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Ann Intern Med. 1994;121:81-89.
FREE FULL TEXT
20. Colwell CW, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J Bone Joint Surg Am. 1994;76:3-14.
FREE FULL TEXT
21. Hamulyak K, Lensing AWA, van der Meer J, Smid WM, van Ooy A, Hoek JA. Subcutaneous low molecular weight heparin or oral anticoagulants for the prevention of deep vein thrombosis in elective hip and knee replacement? Thromb Haemost. 1995;74:1428-1431.
ISI
| PUBMED
22. Bergqvist D, Benoni G, Bjorgell O, et al. Low molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335:696-700.
FREE FULL TEXT
23. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of enoxaparin versus placebo. Lancet. 1996;348:224-228.
FULL TEXT
|
ISI
| PUBMED
24. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery: results of a double-blind prospective, randomized, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost. 1997;77:26-31.
ISI
| PUBMED
25. Francis CW, Pellegrini VD, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty: comparison of warfarin and dalteparin. J Bone Joint Surg Am. 1997;79:1365-1372.
FREE FULL TEXT
26. Eriksson B, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997;337:1329-1335.
FREE FULL TEXT
27. Samama CM, Clergue F, Barre J, Montefiore A, Ill P, Samii K. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Br J Anaesth. 1997;78:660-665.
FREE FULL TEXT
28. Lassen MR, Borris LC, Andersen BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low-molecular-weight heparin (dalteparin) after total hip-arthroplasty: the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res. 1998;89:281-287.
FULL TEXT
|
ISI
| PUBMED
29. Planes A, Samama M, Lensing A, et al. Prevention of deep vein thrombosis after total hip replacement: comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb Haemost. 1999;81:22-25.
ISI
| PUBMED
30. Sharnoff JG, DeBlasio G. Prevention of fatal postoperative thromboembolism by heparin prophylaxis. Lancet. 1970;2:1006-1007.
ISI
| PUBMED
31. Gallus AS, Hirsh J, Tuttle RJ, et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med. 1973;288:545-551.
32. Kearon C, Hirsh J. Starting prophylaxis for venous thromboembolism postoperatively. Arch Intern Med. 1995;155:366-372.
FREE FULL TEXT
33. Hull RD, Brant RF, Pineo GF, Stein PD, Raskob GE, Valentine KA. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med. 1999;159:137-141.
FREE FULL TEXT
34. Vandermeulen EP, van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg. 1994;79:1165-1177.
FREE FULL TEXT
35. Hull RD, Raskob GE, Pineo GF, Brant R. A standardized prescriptive warfarin sodium nomogram [abstract]. Clin Res. 1994;42:185A.
36. Paiement G, Wessinger SJ, Waltman AC, Harris WH. Surveillance of deep vein thrombosis in asymptomatic total hip replacement patients: impedance phlebography and fibrinogen scanning vs roentogenographic phlebography. Am J Surg. 1988;155:400-404.
ISI
| PUBMED
37. Comerota AJ, Katz ML, Grossi RJ, White JV. The comparative value of noninvasive testing for diagnosis and surveillance of deep vein thrombosis. J Vasc Surg. 1988;7:40-49.
FULL TEXT
|
ISI
| PUBMED
38. Borris LC, Christiansen HM, Lassen MR, Olsen AD, Schott P. Comparison of real-time B-mode ultrasonography and bilateral ascending phlebography for detection of post-operative deep vein thrombosis following elective hip surgery: the Venous Thrombosis Group. Thromb Haemost. 1989;61:363-365.
ISI
| PUBMED
39. Ginsberg JS, Caco CC, Brill-Edwards PA, et al. Venous thrombosis in patients who have undergone major hip or knee surgery: detection with compression US and impedance plethysmography. Radiology. 1991;181:651-654.
FREE FULL TEXT
40. Davidson BL, Elliott CG, Lensing AWA, for the RD Heparin Arthroplasty Group. Low accuracy of color Doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high-risk patients. Ann Intern Med. 1992;117:735-738.
41. Wells PS, Lensing AW, Davidson BL, Prins MH, Hirsh J. Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery: a meta-analysis. Ann Intern Med. 1995;122:47-53.
FREE FULL TEXT
42. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg. 1972;104:134-144.
FREE FULL TEXT
43. Hull RD, Raskob GE, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA. 1990;263:2313-2317.
FREE FULL TEXT
44. Hull RD, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301:855-858.
ABSTRACT
45. Graafsma YP, Prins MH, Lensing WA, de Haan RJ, Huisman MV, Buller HR. Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost. 1997;78:1189-1192.
ISI
| PUBMED
46. PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA. 1990;263:2753-2769.
FREE FULL TEXT
47. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest. 1985;88:819-828.
FREE FULL TEXT
48. Bookstein JJ, Silver TM. The angiographic differential diagnosis of acute pulmonary embolism. Radiology. 1974;110:25-33.
ISI
| PUBMED
49. Armitage P, Berry G. Statistical Methods in Medical Research. 2nd ed. Malden, Mass: Blackwell Publishers; 1987:93-407.
50. Francis CW, Pellegrini VD Jr, Marder VJ, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA. 1992;267:2911-2915.
FREE FULL TEXT
51. Lumpkin MM. FDA alert: FDA public health advisory. Anesthesiology. 1998;88:27A-28A.
52. Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens and guidelines for regional anesthetic management. Anesth Analg. 1997;85:874-885.
FULL TEXT
|
ISI
| PUBMED
53. Horlocker TT, Wedel DJ. Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med. 1998;6(suppl 2):164-177.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients: A Double-blind, Randomized Comparison
Russell D. Hull, Graham F. Pineo, Charles Francis, David Bergqvist, Carin Fellenius, Karin Soderberg, Anna Holmqvist, Michael Mant, Richard Dear, Barry Baylis, Andrew Mah, Rollin Brant, and for the North American Fragmin Trial Investigators
Arch Intern Med. 2000;160(14):2208-2215.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings
Nutescu et al.
The Annals of Pharmacotherapy 2009;43:1064-1083.
ABSTRACT
| FULL TEXT
Prevention of Symptomatic Pulmonary Embolism in Patients Undergoing Total Hip or Knee Arthroplasty
Johanson et al.
J Am Acad Orthop Surg 2009;17:183-196.
ABSTRACT
| FULL TEXT
Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Geerts et al.
Chest 2008;133:381S-453S.
ABSTRACT
| FULL TEXT
Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents
Crowther and Warkentin
Blood 2008;111:4871-4879.
ABSTRACT
| FULL TEXT
Optimal Duration of Prophylaxis for Venous Thromboembolism Following Total Hip Arthroplasty and Total Knee Arthroplasty
Friedman
J Am Acad Orthop Surg 2007;15:148-155.
ABSTRACT
| FULL TEXT
Proximal Deep Vein Thrombosis After Hip Replacement for Oncologic Indications
Nathan et al.
JBJS 2006;88:1066-1070.
ABSTRACT
| FULL TEXT
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
Lieberman and Hsu
JBJS 2005;87:2097-2112.
ABSTRACT
| FULL TEXT
Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement
Stangier et al.
J Clin Pharmacol 2005;45:555-563.
ABSTRACT
| FULL TEXT
Neuraxial Anesthesia and Low-Molecular-Weight Heparin Prophylaxis in Major Orthopedic Surgery in the Wake of the Latest American Society of Regional Anesthesia Guidelines
Rowlingson and Hanson
Anesth. Analg. 2005;100:1482-1488.
ABSTRACT
| FULL TEXT
Efficacy and Safety of Fixed Low-Dose Dalteparin in Preventing Venous Thromboembolism Among Obese or Elderly Hospitalized Patients: A Subgroup Analysis of the PREVENT Trial
Kucher et al.
Arch Intern Med 2005;165:341-345.
ABSTRACT
| FULL TEXT
Prevention of Venous Thromboembolism in Surgical Patients
Agnelli
Circulation 2004;110:IV-4-IV-12.
ABSTRACT
| FULL TEXT
Therapeutic Update on the Prevention and Treatment of Venous Thromboembolism
McGuire and Dobesh
Journal of Pharmacy Practice 2004;17:289-307.
ABSTRACT
Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Geerts et al.
Chest 2004;126:338S-400S.
ABSTRACT
| FULL TEXT
Regional block and DVT prophylaxis
Checketts and Wildsmith
Contin Educ Anaesth Crit Care Pain 2004;4:48-51.
ABSTRACT
| FULL TEXT
New Pentasaccharides for the Prophylaxis of Venous Thromboembolism: Clinical Studies
Turpie et al.
Chest 2003;124
:371S-378S.
ABSTRACT
| FULL TEXT
Controversies in Timing of the First Dose of Anticoagulant Prophylaxis Against Venous Thromboembolism After Major Orthopedic Surgery
Raskob and Hirsh
Chest 2003;124
:379S-385S.
ABSTRACT
| FULL TEXT
Venous Thromboembolism Prevention with LMWHs in Medical and Orthopedic Surgery Patients
Deitelzweig et al.
The Annals of Pharmacotherapy 2003;37:402-411.
ABSTRACT
| FULL TEXT
Reporting the NAFT Major Bleeding Rates in Context: Reviewers Should Include Site Investigator-Classified Rates
Hull and Mah
Arch Intern Med 2003;163:369-369.
FULL TEXT
Extended Venous Thromboembolism Prophylaxis After Total Hip Replacement: A Comparison of Low-Molecular-Weight Heparin With Oral Anticoagulant
Samama et al.
Arch Intern Med 2002;162:2191-2196.
ABSTRACT
| FULL TEXT
The Potential Role of Fondaparinux as Venous Thromboembolism Prophylaxis After Total Hip or Knee Replacement or Hip Fracture Surgery
Heit
Arch Intern Med 2002;162:1806-1808.
FULL TEXT
Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery: A Meta-analysis of 4 Randomized Double-blind Studies
Turpie et al.
Arch Intern Med 2002;162:1833-1840.
ABSTRACT
| FULL TEXT
Low-Molecular-Weight Heparin
Whang and Lieberman
J Am Acad Orthop Surg 2002;10:299-302.
FULL TEXT
Preoperative or Postoperative Start of Prophylaxis for Venous Thromboembolism With Low-Molecular-Weight Heparin in Elective Hip Surgery?
Strebel et al.
Arch Intern Med 2002;162:1451-1456.
ABSTRACT
| FULL TEXT
Short-Duration Prophylaxis Against Venous Thromboembolism After Total Hip or Knee Replacement: A Meta-analysis of Prospective Studies Investigating Symptomatic Outcomes
Douketis et al.
Arch Intern Med 2002;162:1465-1471.
ABSTRACT
| FULL TEXT
Prevention of Venous Thromboembolism with Fondaparinux
Murashige et al.
NEJM 2002;346:940-942.
FULL TEXT
Prophylaxis Against Venous Thromboembolic Disease in Patients Having a Total Hip or Knee Arthroplasty
Sculco et al.
JBJS 2002;84:466-477.
FULL TEXT
Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty: A Systematic Review
Hull et al.
ANN INTERN MED 2001;135:858-869.
ABSTRACT
| FULL TEXT
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture Surgery
Eriksson et al.
NEJM 2001;345:1298-1304.
ABSTRACT
| FULL TEXT
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery
Bauer et al.
NEJM 2001;345:1305-1310.
ABSTRACT
| FULL TEXT
Timing of Initial Administration of Low-Molecular-Weight Heparin Prophylaxis Against Deep Vein Thrombosis in Patients Following Elective Hip Arthroplasty: A Systematic Review
Hull et al.
Arch Intern Med 2001;161:1952-1960.
ABSTRACT
| FULL TEXT
A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis
Hull et al.
NEJM 2001;345:291-292.
FULL TEXT
Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement
Lee et al.
Circulation 2001;104:74-78.
ABSTRACT
| FULL TEXT
Warfarin Therapy for an Octogenarian Who Has Atrial Fibrillation
Gage et al.
ANN INTERN MED 2001;134:465-474.
ABSTRACT
| FULL TEXT
Dalteparin vs Warfarin in Hip Arthroplasty Patients
Bajjoka et al.
Arch Intern Med 2001;161:776-777.
FULL TEXT
Prevention of Venous Thromboembolism
Geerts et al.
Chest 2001;119
:132S-175S.
FULL TEXT
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients: A Double-blind, Randomized Comparison
Hull et al.
Arch Intern Med 2000;160:2208-2215.
ABSTRACT
| FULL TEXT
|
